Hunan Warrant Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A carries a market capitalization of 6.00B, placing it among publicly traded companies globally. Its enterprise value stands at 6.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hunan Warrant Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A has 133.64M shares outstanding.

As of June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 47.24. The price-to-sales ratio is 4.08, and the price-to-book ratio stands at 2.82.

As of June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 50.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 50.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.48B versus a market cap of 6.00B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.57, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.45, indicating elevated leverage, while an interest coverage ratio of 50.69 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 6.32, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.88 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.42, useful for judging operating efficiency across full business cycles. The company generates approximately 1.14M in revenue per employee across its workforce of 1,277.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.53 indicates how many times Hunan Warrant Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A recorded 7.70M in income tax expense. That works out to an effective tax rate of 6.00, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 128.33M, leaving 125.66M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A's stock has declined approximately 5.79% over the past 52 weeks. The 50-day moving average sits at 48.74, while the 200-day moving average is 49.81.

Over the twelve months ended June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A generated 1.46B in revenue and converted that into 125.66M in net income, yielding earnings per share of 0.86. EBITDA reached 128.09M, while operating income came in at 153.43M.

As of June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A holds 288.51M in cash and equivalents against 774.12M in total debt, resulting in a net debt position of 483.53M. Total book value stands at 2.12B, with working capital of 690.34M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A posted a gross margin of 57.88, reflecting its pricing power and cost economics. The operating margin of 10.53 and net profit margin of 8.63 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A paid dividends of 0.60 per share. The dividend payout ratio of 68.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -7.85, meaning Hunan Warrant Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hunan Warrant Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 29, 2025 with a 5:7 split ratio.

As of June 30, 2026, Hunan Warrant Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 4.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.